BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7:35-41. [PMID: 18333159 DOI: 10.1080/13651820410024058] [Cited by in Crossref: 153] [Cited by in F6Publishing: 147] [Article Influence: 12.8] [Reference Citation Analysis]
Number Citing Articles
1 Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012;10:354-362. [PMID: 22083023 DOI: 10.1016/j.cgh.2011.11.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
2 Banerjee S, Wang DS, Kim HJ, Sirlin CB, Chan MG, Korn RL, Rutman AM, Siripongsakun S, Lu D, Imanbayev G, Kuo MD. A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology 2015;62:792-800. [PMID: 25930992 DOI: 10.1002/hep.27877] [Cited by in Crossref: 145] [Cited by in F6Publishing: 145] [Article Influence: 20.7] [Reference Citation Analysis]
3 Sarpel U, Heskel M, Spivack JH, Feferman Y, Ang C, Gany F. Disparities in Access to Sorafenib in Communities with Low Socioeconomic Status. J Health Care Poor Underserved 2018;29:1123-34. [PMID: 30122687 DOI: 10.1353/hpu.2018.0083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Huang Y, Zhang Z, Liao W, Hu K, Wang Z. Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study. Front Oncol 2021;11:650394. [PMID: 34408974 DOI: 10.3389/fonc.2021.650394] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Fathy AH, Bashandy MA, Bashandy SA, Mansour AM, Elsadek B. Sequential analysis and staging of a diethylnitrosamine-induced hepatocellular carcinoma in male Wistar albino rat model. Can J Physiol Pharmacol 2017;95:1462-72. [DOI: 10.1139/cjpp-2017-0413] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
6 Meloni MF, Chiang J, Laeseke PF, Dietrich CF, Sannino A, Solbiati M, Nocerino E, Brace CL, Lee FT Jr. Microwave ablation in primary and secondary liver tumours: technical and clinical approaches. Int J Hyperthermia 2017;33:15-24. [PMID: 27416729 DOI: 10.1080/02656736.2016.1209694] [Cited by in Crossref: 51] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
7 Park GC, Hwang S, Park YH, Choi JU; Korean Liver Cancer Study Group. Validation of prognostic impact of ADV score for resection of hepatocellular carcinoma: analysis using Korea Liver Cancer Registry Database. Ann Surg Treat Res 2020;98:235-46. [PMID: 32411628 DOI: 10.4174/astr.2020.98.5.235] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Ahmed O, Vachharajani N, Chang SH, Park Y, Khan AS, Chapman WC, Doyle MB. Access to Liver Transplantation for Hepatocellular Carcinoma: Does Candidate Age Matter? J Am Coll Surg 2021;233:140-51. [PMID: 33652155 DOI: 10.1016/j.jamcollsurg.2021.01.018] [Reference Citation Analysis]
9 Cai J, Chen L, Zhang Z, Zhang X, Lu X, Liu W, Shi G, Ge Y, Gao P, Yang Y, Ke A, Xiao L, Dong R, Zhu Y, Yang X, Wang J, Zhu T, Yang D, Huang X, Sui C, Qiu S, Shen F, Sun H, Zhou W, Zhou J, Nie J, Zeng C, Stroup EK, Chiu BC, Lau WY, He C, Wang H, Zhang W, Fan J. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019;68:2195-2205. [PMID: 31358576 DOI: 10.1136/gutjnl-2019-318882] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 19.7] [Reference Citation Analysis]
10 Long J, Zhang L, Wan X, Lin J, Bai Y, Xu W, Xiong J, Zhao H. A four-gene-based prognostic model predicts overall survival in patients with hepatocellular carcinoma. J Cell Mol Med. 2018;22:5928-5938. [PMID: 30247807 DOI: 10.1111/jcmm.13863] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 14.0] [Reference Citation Analysis]
11 Graf D, Vallböhmer D, Knoefel WT, Kröpil P, Antoch G, Sagir A, Häussinger D. Multimodal treatment of hepatocellular carcinoma. Eur J Intern Med. 2014;25:430-437. [PMID: 24666568 DOI: 10.1016/j.ejim.2014.03.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
12 Wu G, Wu J, Wang B, Zhu X, Shi X, Ding Y. Importance of tumor size at diagnosis as a prognostic factor for hepatocellular carcinoma survival: a population-based study. Cancer Manag Res 2018;10:4401-10. [PMID: 30349373 DOI: 10.2147/CMAR.S177663] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
13 Demirtas CO, D'Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep 2021;3:100347. [PMID: 34505035 DOI: 10.1016/j.jhepr.2021.100347] [Reference Citation Analysis]
14 Sheppard-Law S, Zablotska-Manos I, Kermeen M, Holdaway S, Lee A, George J, Zekry A, Maher L. Utilisation of hepatocellular carcinoma screening in Australians at risk of hepatitis B virus-related carcinoma and prescribed anti-viral therapy. J Clin Nurs 2018;27:2673-83. [PMID: 29603817 DOI: 10.1111/jocn.14367] [Reference Citation Analysis]
15 Marrero J, Maluccio MA, McCurdy H, Abou-Alfa GK. Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma. Cancer Control 2014;21:5-16. [PMID: 24681845 DOI: 10.1177/1073274814021002s02] [Reference Citation Analysis]
16 Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, Gerken G, Antoch G. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52:1741-9. [DOI: 10.1002/hep.23944] [Cited by in Crossref: 267] [Cited by in F6Publishing: 245] [Article Influence: 22.3] [Reference Citation Analysis]
17 Acher AW, Abbott DE. Rethinking Resection and Transplant Candidacy for HCC: Should Tumor Biology Replace Size-Based Criteria? Ann Surg Oncol 2020;27:1309-11. [PMID: 31728794 DOI: 10.1245/s10434-019-08081-5] [Reference Citation Analysis]
18 Lam T, Wong W, Lee C, Cheung C. Transarterial chemoembolisation plus stereotactic body radiotherapy as conversion therapy for large right lobe hepatocecullar carcinoma. Surgical Practice 2021;25:211-7. [DOI: 10.1111/1744-1633.12530] [Reference Citation Analysis]
19 Nam BH, Park JW, Jeong SH, Lee SS, Yu A, Kim BH, Kim WR. Korean Version of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma (K-MESIAH). PLoS One 2015;10:e0138374. [PMID: 26488298 DOI: 10.1371/journal.pone.0138374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Sohn W, Paik Y, Lee MW, Rhim H, Lim HK, Cho JY, Gwak G, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Predisposing factors for recurrence of HBV-related small hepatocellular carcinoma after percutaneous radiofrequency ablation. Scandinavian Journal of Gastroenterology 2013;49:373-80. [DOI: 10.3109/00365521.2013.871745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
21 Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16:859-70. [PMID: 26095784 DOI: 10.1016/S1470-2045(15)00050-9] [Cited by in Crossref: 419] [Cited by in F6Publishing: 246] [Article Influence: 59.9] [Reference Citation Analysis]
22 Sohn W, Paik YH, Cho JY, Ahn JM, Choi GS, Kim JM, Kwon CH, Joh JW, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load. J Viral Hepat 2015;22:539-50. [PMID: 25377516 DOI: 10.1111/jvh.12356] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
23 Cho Y, Lee JH, Lee DH, Cho EJ, Yu SJ, Yi NJ, Lee KW, Kim YJ, Yoon JH, Suh KS. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. Oncotarget 2017;8:47555-64. [PMID: 28548930 DOI: 10.18632/oncotarget.17733] [Reference Citation Analysis]
24 Arellano RS. What's New in Percutaneous Ablative Strategies for Hepatocellular Carcinoma and Colorectal Hepatic Metastases? 2020 Update. Curr Oncol Rep 2020;22:105. [PMID: 32725433 DOI: 10.1007/s11912-020-00967-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Wang W, Lv J, Chen N, Lou B, Mao W, Wang P, Chen Y. Dysregulated serum metabolites in staging of hepatocellular carcinoma. Clin Biochem 2018;61:7-11. [PMID: 30195484 DOI: 10.1016/j.clinbiochem.2018.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Wang L, Liu Z, Liu X, Zeng Y, Liu J. The hepatectomy efficacy of huge hepatocellular carcinoma and its risk factors: A meta analysis. Medicine (Baltimore) 2017;96:e9226. [PMID: 29384907 DOI: 10.1097/MD.0000000000009226] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
27 Yin L, Wang Y, Guo X, Xu C, Yu G. Comparison of gene expression in liver regeneration and hepatocellular carcinoma formation. Cancer Manag Res 2018;10:5691-708. [PMID: 30532592 DOI: 10.2147/CMAR.S172945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
28 Lewis S, Dawson L, Barry A, Stanescu T, Mohamad I, Hosni A. Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100498] [Reference Citation Analysis]
29 Li B, Liu W, Wang L, Li M, Wang J, Huang L, Huang P, Yuan Y. CpG island methylator phenotype associated with tumor recurrence in tumor-node-metastasis stage I hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1917-1926. [PMID: 20112070 DOI: 10.1245/s10434-010-0921-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
30 Bliznakova K, Kolev N, Buliev I, Tonev A, Encheva E, Bliznakov Z, Ivanov K. Computer aided preoperative evaluation of the residual liver volume using computed tomography images. J Digit Imaging 2015;28:231-9. [PMID: 25273505 DOI: 10.1007/s10278-014-9737-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
31 Chuncharunee A, Siramolpiwat S. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment. Asian Pac J Cancer Prev 2017;18:1697-701. [PMID: 28670891 DOI: 10.22034/APJCP.2017.18.6.1697] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
32 Fuster J. Surgical treatment of hepatocellular carcinoma: should resection be performed according to Barcelona Clinic Liver Cancer classification? Hepat Oncol 2015;2:245-53. [PMID: 30191006 DOI: 10.2217/hep.15.18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
33 Koudelkova P, Costina V, Weber G, Dooley S, Findeisen P, Winter P, Agarwal R, Schlangen K, Mikulits W. Transforming Growth Factor-β Drives the Transendothelial Migration of Hepatocellular Carcinoma Cells. Int J Mol Sci 2017;18:E2119. [PMID: 28994702 DOI: 10.3390/ijms18102119] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
34 Wai LE, Narang V, Gouaillard A, Ng LG, Abastado JP. In silico modeling of cancer cell dissemination and metastasis. Ann N Y Acad Sci 2013;1284:71-4. [PMID: 23651197 DOI: 10.1111/nyas.12077] [Reference Citation Analysis]
35 Hoffe SE, Finkelstein SE, Russell MS, Shridhar R. Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy. Cancer Control 2010;17:100-10. [PMID: 20404793 DOI: 10.1177/107327481001700205] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
36 Gryziak M, Woźniak K, Kraj L, Stec R. Milestones in the treatment of hepatocellular carcinoma: A systematic review. Critical Reviews in Oncology/Hematology 2021;157:103179. [DOI: 10.1016/j.critrevonc.2020.103179] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
37 He H, Yi Y, Cai X, Wang J, Ni X, Fu Y, Qiu S. Down-regulation of EOMES drives T-cell exhaustion via abolishing EOMES-mediated repression of inhibitory receptors of T cells in liver cancer. J Cell Mol Med 2021;25:161-9. [PMID: 33325636 DOI: 10.1111/jcmm.15898] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Kim S, Chughtai K, Brahmbhatt A, Rubens D, Dogra V. Contrast-Enhanced Ultrasound as a Problem-Solving Modality: Tips and Tricks. Ultrasound Q 2022. [PMID: 35426378 DOI: 10.1097/RUQ.0000000000000604] [Reference Citation Analysis]
39 Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, Geschwind JF, Doyle MB, Abou-Alfa GK, Are C. A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Ann Surg. 2016;263:1112-1125. [PMID: 26813914 DOI: 10.1097/sla.0000000000001556] [Cited by in Crossref: 124] [Cited by in F6Publishing: 86] [Article Influence: 24.8] [Reference Citation Analysis]
40 Sohn W, Paik YH, Cho JY, Lim HY, Ahn JM, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. J Hepatol. 2015;62:1112-1121. [PMID: 25514557 DOI: 10.1016/j.jhep.2014.12.009] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
41 Azad I, Jafri A, Khan T, Akhter Y, Arshad M, Hassan F, Ahmad N, Khan AR, Nasibullah M. Evaluation of pyrrole-2,3-dicarboxylate derivatives: Synthesis, DFT analysis, molecular docking, virtual screening and in vitro anti-hepatic cancer study. Journal of Molecular Structure 2019;1176:314-34. [DOI: 10.1016/j.molstruc.2018.08.049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
42 Yin L, Mu Y, Lin Y, Xia Q. HGFAC expression decreased in liver cancer and its low expression correlated with DNA hypermethylation and poor prognosis. J Cell Biochem 2019;120:9692-9. [PMID: 30635948 DOI: 10.1002/jcb.28247] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
43 Patterson AD, Maurhofer O, Beyoglu D, Lanz C, Krausz KW, Pabst T, Gonzalez FJ, Dufour JF, Idle JR. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res. 2011;71:6590-6600. [PMID: 21900402 DOI: 10.1158/0008-5472.can-11-0885] [Cited by in Crossref: 182] [Cited by in F6Publishing: 96] [Article Influence: 16.5] [Reference Citation Analysis]
44 Eltawil KM, Berry R, Abdolell M, Molinari M. Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study. HPB (Oxford). 2012;14:341-350. [PMID: 22487072 DOI: 10.1111/j.1477-2574.2012.00455.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
45 Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014;68:609-17. [PMID: 24283303 DOI: 10.1111/ijcp.12352] [Cited by in Crossref: 154] [Cited by in F6Publishing: 140] [Article Influence: 17.1] [Reference Citation Analysis]
46 Li LM, Chen C, Ran RX, Huang JT, Sun HL, Zeng C, Zhang Z, Zhang W, Liu SM. Loss of TARBP2 Drives the Progression of Hepatocellular Carcinoma via miR-145-SERPINE1 Axis. Front Oncol 2021;11:620912. [PMID: 34249676 DOI: 10.3389/fonc.2021.620912] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Chan SL, Mo FK, Johnson PJ, Liem GS, Chan TC, Poon MC, Ma BB, Leung TW, Lai PB, Chan AT. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol. 2011;26:340-347. [PMID: 21261725 DOI: 10.1111/j.1440-1746.2010.06329.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 5.3] [Reference Citation Analysis]
48 Abouelezz K, Khanapara D, Batiha GE, Ahmed EA, Hetta HF. Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries. Cancer Manag Res 2020;12:12239-48. [PMID: 33273860 DOI: 10.2147/CMAR.S280631] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Zhang S, Lin J, Jiang J, Chen Y, Tang W, Liu L. Association between methylenetetrahydrofolate reductase tagging polymorphisms and susceptibility of hepatocellular carcinoma: a case-control study. Biosci Rep 2019;39:BSR20192517. [PMID: 31694048 DOI: 10.1042/BSR20192517] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Srivastava A, Jong S, Gola A, Gailer R, Morgan S, Sennett K, Tanwar S, Pizzo E, O'Beirne J, Tsochatzis E, Parkes J, Rosenberg W. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterol 2019;19:122. [PMID: 31296161 DOI: 10.1186/s12876-019-1039-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
51 Huber TC, Bochnakova T, Koethe Y, Park B, Farsad K. Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies. J Hepatocell Carcinoma 2021;8:1181-93. [PMID: 34589446 DOI: 10.2147/JHC.S268300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao L, Morris JS, Macapinlac HA, Hassan MM, Kaseb AO. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol Imaging 2017;44:969-78. [PMID: 27942837 DOI: 10.1007/s00259-016-3583-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
53 Aigelsreiter A, Ress AL, Bettermann K, Schauer S, Koller K, Eisner F, Kiesslich T, Stojakovic T, Samonigg H, Kornprat P, Lackner C, Haybaeck J, Pichler M. Low expression of the putative tumour suppressor spinophilin is associated with higher proliferative activity and poor prognosis in patients with hepatocellular carcinoma. Br J Cancer 2013;108:1830-7. [PMID: 23591196 DOI: 10.1038/bjc.2013.165] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
54 Wong K, Xu Z, Chen J, Lee NP, Luk JM. Circulating markers for prognosis of hepatocellular carcinoma. Expert Opinion on Medical Diagnostics 2013;7:319-29. [DOI: 10.1517/17530059.2013.795146] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
55 Chan SL, Johnson P. Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: An Asian perspective: Editorial. Asia-Pacific Journal of Clinical Oncology 2012;8:111-4. [DOI: 10.1111/j.1743-7563.2012.01551.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
56 Lu C, Jia S, Zhao S, Shao X. MiR-342 regulates cell proliferation and apoptosis in hepatocellular carcinoma through Wnt/β-catenin signaling pathway. CBM 2019;25:115-26. [DOI: 10.3233/cbm-192399] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
57 Zheng JS, Long J, Sun B, Lu NN, Fang D, Zhao LY, Du N. Transcatheter arterial chemoembolization combined with radiofrequency ablation can improve survival of patients with hepatocellular carcinoma with portal vein tumour thrombosis: extending the indication for ablation? Clin Radiol. 2014;69:e253-e263. [PMID: 24581962 DOI: 10.1016/j.crad.2014.01.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
58 Lee DW, Yim HJ, Seo YS, Na SK, Kim SY, Suh SJ, Hyun JJ, Jung SW, Jung YK, Koo JS, Kim JH, Yeon JE, Lee SW, Byun KS, Um SH. Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study. Liver Int. 2019;39:1109-1119. [PMID: 30972935 DOI: 10.1111/liv.14117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Zhu R, Guo W, Xu XJ, Zhu L. An Integrating Immune-Related Signature to Improve Prognosis of Hepatocellular Carcinoma. Comput Math Methods Med 2020;2020:8872329. [PMID: 33204302 DOI: 10.1155/2020/8872329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
60 McDevitt JL, Alian A, Kapoor B, Bennett S, Gill A, Levitin A, Sands M, Narayanan Menon KV, Aucejo FN, Estfan B, Pillai AK, Kalva SP, McLennan G. Single-Center Comparison of Overall Survival and Toxicities in Patients with Infiltrative Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization or Drug-Eluting Embolic Transarterial Chemoembolization. J Vasc Interv Radiol 2017;28:1371-7. [PMID: 28689934 DOI: 10.1016/j.jvir.2017.05.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
61 Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr Oncol Rep. 2012;14:257-266. [PMID: 22434314 DOI: 10.1007/s11912-11012-10233-11910] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Aberra FB, Essenmacher M, Fisher N, Volk ML. Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci. 2013;58:1157-1160. [PMID: 23111632 DOI: 10.1007/s10620-012-2461-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
63 Rein-fischboeck L, Pohl R, Haberl EM, Zimny S, Neumann M, Eisinger K, Weiss TS, Krautbauer S, Buechler C. Tubulin alpha 8 is expressed in hepatic stellate cells and is induced in transformed hepatocytes. Mol Cell Biochem 2017;428:161-70. [DOI: 10.1007/s11010-016-2926-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
64 Swersky A, Kulik L, Kalyan A, Grace K, Caicedo JC, Lewandowski RJ, Salem R. Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach. Semin Intervent Radiol 2021;38:432-7. [PMID: 34629710 DOI: 10.1055/s-0041-1735528] [Reference Citation Analysis]
65 He X, Xu H, Wang X, Wu J, Niu J, Gao P. Associations between the single nucleotide polymorphisms of APOBEC3A, APOBEC3B and APOBEC3H, and chronic hepatitis B progression and hepatocellular carcinoma in a Chinese population. Mol Med Rep 2019;20:2177-88. [PMID: 31322199 DOI: 10.3892/mmr.2019.10455] [Reference Citation Analysis]
66 Venkatesh SK, Chandan V, Roberts LR. Liver masses: a clinical, radiologic, and pathologic perspective. Clin Gastroenterol Hepatol. 2014;12:1414-1429. [PMID: 24055987 DOI: 10.1016/j.cgh.2013.09.017] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
67 Deshpande R, O'Reilly D, Sherlock D. Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC. Int J Hepatol 2011;2011:686074. [PMID: 21994867 DOI: 10.4061/2011/686074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
68 Bethge A, Schumacher U, Wree A, Wedemann G. Are metastases from metastases clinical relevant? Computer modelling of cancer spread in a case of hepatocellular carcinoma. PLoS One. 2012;7:e35689. [PMID: 22539992 DOI: 10.1371/journal.pone.0035689] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
69 Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Méndez-Sánchez N, Yuen MF, Hwang JP. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book 2018;38:262-79. [PMID: 30231359 DOI: 10.1200/EDBK_200939] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 15.5] [Reference Citation Analysis]
70 Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014;273:30-50. [PMID: 25247563 DOI: 10.1148/radiol.14132362] [Cited by in Crossref: 256] [Cited by in F6Publishing: 208] [Article Influence: 36.6] [Reference Citation Analysis]
71 Sahakyan MA, Kazaryan AM, Pomianowska E, Abildgaard A, Line PD, Bjørnbeth BA, Edwin B, Røsok BI. Laparoscopic Resection of Recurrence from Hepatocellular Carcinoma after Liver Transplantation: Case Reports and Review of the Literature. Case Rep Oncol Med 2016;2016:8946471. [PMID: 27034867 DOI: 10.1155/2016/8946471] [Reference Citation Analysis]
72 Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. Open Access Maced J Med Sci. 2015;3:732-736. [PMID: 27275318 DOI: 10.3889/oamjms.2015.111] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
73 Lee EW, Alanis L, Cho SK, Saab S. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. Korean J Radiol. 2016;17:472-488. [PMID: 27390539 DOI: 10.3348/kjr.2016.17.4.472] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
74 Selvapatt N, House H, Brown A. Hepatocellular Carcinoma Surveillance: Are We Utilizing It? J Clin Gastroenterol 2016;50:e8-e12. [PMID: 26018132 DOI: 10.1097/MCG.0000000000000344] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
75 Patkar S, Parray A, Mahendra B, Kurunkar S, Goel M. Performance of Hong Kong Liver Cancer staging system in patients of hepatocellular carcinoma treated with surgical resection: An Indian validation study. J Surg Oncol 2019;120:1119-25. [PMID: 31549392 DOI: 10.1002/jso.25704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Sun JH, Zhou T, Zhu T, Zhang Y, Nie C, Ai J, Zhou G, Zhang A, Dong MJ, Wang WL, Zheng SS. Portal Vein Stenting Combined with Iodine-125 Seeds Endovascular Implantation Followed by Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus. Biomed Res Int. 2016;2016:3048261. [PMID: 27999793 DOI: 10.1155/2016/3048261] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
77 Chi X, Jiang L, Yuan Y, Huang X, Yang X, Hochwald S, Liu J, Huang H. A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02279-w] [Reference Citation Analysis]
78 Wahab MA, Shehta A, Hamed H, El Nakeeb A, Salah T. Predictors of recurrence in hepatitis C virus related hepatocellular carcinoma after hepatic resection: a retrospective cohort study. Eurasian J Med 2014;46:36-41. [PMID: 25610292 DOI: 10.5152/eajm.2014.07] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
79 Waly Raphael S, Yangde Z, Yuxiang C. Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol 2012;2012:421673. [PMID: 22655206 DOI: 10.5402/2012/421673] [Cited by in Crossref: 25] [Cited by in F6Publishing: 45] [Article Influence: 2.5] [Reference Citation Analysis]
80 Zeng XC, Liu FQ, Yan R, Yi HM, Zhang T, Wang GY, Li Y, Jiang N. Downregulation of miR-610 promotes proliferation and tumorigenicity and activates Wnt/β-catenin signaling in human hepatocellular carcinoma. Mol Cancer 2014;13:261. [PMID: 25491321 DOI: 10.1186/1476-4598-13-261] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
81 Huang LF, Xing X, Wu D, Xia Y, Li J, Wang K, Yan ZL, Wan XY, Shi LH, Yang T, Lau WY, Wu MC, Shen F. A novel scoring system predicts adjuvant chemolipiodolization benefit for hepatocellular carcinoma patients after hepatectomy. Oncotarget 2016;7:25493-506. [PMID: 27027439 DOI: 10.18632/oncotarget.8333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
82 Colussi G, Donnini D, Brizzi RF, Maier S, Valenti L, Catena C, Cavarape A, Sechi LA, Soardo G. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. World J Gastroenterol 2019; 25(40): 6094-6106 [PMID: 31686765 DOI: 10.3748/wjg.v25.i40.6094] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
83 Chen LJ, Chang YJ, Chang YJ. Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma. Oncologist 2021;26:e445-53. [PMID: 32969134 DOI: 10.1002/onco.13535] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
84 Hassanipour S, Vali M, Gaffari-Fam S, Nikbakht HA, Abdzadeh E, Joukar F, Pourshams A, Shafaghi A, Malakoutikhah M, Arab-Zozani M, Salehiniya H, Mansour-Ghanaei F. The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis. EXCLI J 2020;19:108-30. [PMID: 32038120 DOI: 10.17179/excli2019-1842] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
85 Liu L, Wang B, Han Q, Zhen C, Li J, Qu X, Wang F, Kong X, Zheng L. Bioinformatic Analysis to Identify a Multi-mRNA Signature for the Prediction of Metastasis in Hepatocellular Carcinoma. DNA Cell Biol 2020;39:2028-39. [PMID: 33147069 DOI: 10.1089/dna.2020.5513] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
86 Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Kudo M, Pfiffer T, Hatano E, Chung HC, Kopeckova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Hsu Y, Abada PB, Zhu AX. Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. Br J Cancer 2018;119:19-26. [PMID: 29808014 DOI: 10.1038/s41416-018-0103-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
87 Arai Y. Clinical trials of interventional oncology. Int J Clin Oncol 2012;17:301-5. [PMID: 22836283 DOI: 10.1007/s10147-012-0446-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
88 Chen L, Song L, Shao Y, Li D, Ding K. Using natural language processing to extract clinically useful information from Chinese electronic medical records. Int J Med Inform 2019;124:6-12. [PMID: 30784428 DOI: 10.1016/j.ijmedinf.2019.01.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 6.7] [Reference Citation Analysis]
89 Ferrandino G, Orf I, Smith R, Calcagno M, Thind AK, Debiram-Beecham I, Williams M, Gandelman O, de Saedeleer A, Kibble G, Lydon AM, Mayhew CA, Allsworth M, Boyle B, van der Schee MP, Allison M, Hoare M, Snowdon VK. Breath Biopsy Assessment of Liver Disease Using an Exogenous Volatile Organic Compound-Toward Improved Detection of Liver Impairment. Clin Transl Gastroenterol 2020;11:e00239. [PMID: 33094960 DOI: 10.14309/ctg.0000000000000239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
90 Wu CH, Liang PC, Hsu CH, Chang FT, Shao YY, Ting-Fang Shih T. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma. J Formos Med Assoc 2021;120:559-66. [PMID: 32651043 DOI: 10.1016/j.jfma.2020.07.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
91 Martinez-Mier G, Esquivel-Torres S, Medina Granados JP, Luna-Castillo M, Castillo-Chiquete R, Calzada-Grijalva JF, Gonzalez-Velazquez F. [Presentation, staging, and outcome of patients with hepatocellular carcinoma at a center in Veracruz, Mexico]. Rev Gastroenterol Mex 2014;79:171-9. [PMID: 25236795 DOI: 10.1016/j.rgmx.2014.05.007] [Reference Citation Analysis]
92 Sacco R, Bertini M, Petruzzi P, Bertoni M, Bargellini I, Bresci G, Federici G, Gambardella L, Metrangolo S, Parisi G, Romano A, Scaramuzzino A, Tumino E, Silvestri A, Altomare E, Vignali C, Capria A. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: A cohort study. World J Gastroenterol 2009; 15(15): 1843-1848 [PMID: 19370781 DOI: 10.3748/wjg.15.1843] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
93 Méndez-sánchez N, Gutiérrez-grobe Y. Hepatology Highlights. Annals of Hepatology 2010;9:5-6. [DOI: 10.1016/s1665-2681(19)31672-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
94 Cho ES, Choi JY. MRI features of hepatocellular carcinoma related to biologic behavior. Korean J Radiol. 2015;16:449-464. [PMID: 25995679 DOI: 10.3348/kjr.2015.16.3.449] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
95 Agúndez JA, García-martín E, Devesa MJ, Carballo M, Martínez C, Lee-brunner A, Fernández C, Díaz-rubio M, Ladero JM. Polymorphism of the TLR4 Gene Reduces the Risk of Hepatitis C Virus-Induced Hepatocellular Carcinoma. Oncology 2012;82:35-40. [DOI: 10.1159/000335606] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
96 Kim BH, Park JW, Nam BH, Kwak HW, Kim WR. Validation of a model to estimate survival in ambulatory patients with hepatocellular carcinoma: a single-centre cohort study. Liver Int. 2014;34:e317-e323. [PMID: 24606128 DOI: 10.1111/liv.12519] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
97 Asmis T, Balaa F, Scully L, Papadatos D, Marginean C, Fasih N, Shaw-Stiffel T, Goel R. Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. Curr Oncol 2010;17:6-12. [PMID: 20404972 DOI: 10.3747/co.v17i2.555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
98 Vauthey JN, Dixon E, Abdalla EK, Helton WS, Pawlik TM, Taouli B, Brouquet A, Adams RB; American Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010;12:289-299. [PMID: 20590901 DOI: 10.1111/j.1477-2574.2010.00181.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 99] [Article Influence: 10.1] [Reference Citation Analysis]
99 Tokumitsu Y, Tamesa T, Matsukuma S, Hashimoto N, Maeda Y, Tokuhisa Y, Sakamoto K, Ueno T, Hazama S, Ogihara H. An accurate prognostic staging system for hepatocellular carcinoma patients after curative hepatectomy. Int J Oncol. 2015;46:944-952. [PMID: 25524574 DOI: 10.3892/ijo.2014.2798] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
100 Wang G, Guan J, Yang Q, Wu F, Shao J, Zhou Q, Guo Z, Ren Y, Zhu H, Chen Z, Tang M. Development of a Bile Acid-Related Gene Signature for Predicting Survival in Patients with Hepatocellular Carcinoma. Computational and Mathematical Methods in Medicine 2022;2022:1-14. [DOI: 10.1155/2022/9076175] [Reference Citation Analysis]
101 Chacko S, Samanta S. "Hepatocellular carcinoma: A life-threatening disease". Biomed Pharmacother. 2016;84:1679-1688. [PMID: 27823920 DOI: 10.1016/j.biopha.2016.10.078] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
102 Juratli MA, Struecker B, Katou S, Morguel MH, Pascher A. [Influence of molecular pathology on oncological surgery of liver and bile duct tumors]. Chirurg 2021;92:1003-10. [PMID: 34519849 DOI: 10.1007/s00104-021-01495-6] [Reference Citation Analysis]
103 Li IH, Shih JH, Tsai CS, Chien WC, Kao HH, Pan KT, Cheng YD, Kao LT. Inverse Association of Fibrates and Liver Cancer: A Population-Based Case-Control Study in Taiwan. J Clin Pharmacol 2019;59:1170-6. [PMID: 30964561 DOI: 10.1002/jcph.1419] [Reference Citation Analysis]
104 McDevitt JL, Collard MD, Murphy RP, Sutphin PD, Yopp AC, Singal AG, Kalva SP. Comparison of radiofrequency and microwave ablation and identification of risk factors for primary treatment failure and local progression. Clin Imaging 2020;67:146-51. [PMID: 32659600 DOI: 10.1016/j.clinimag.2020.06.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
105 Luu HM, Moelker A, Klein S, Niessen W, van Walsum T. Quantification of nonrigid liver deformation in radiofrequency ablation interventions using image registration. Phys Med Biol 2018;63:175005. [DOI: 10.1088/1361-6560/aad706] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
106 Sobotka L, Hinton A, Conteh L. Women receive more inpatient resections and ablations for hepatocellular carcinoma than men. World J Hepatol 2017; 9(36): 1346-1351 [PMID: 29359018 DOI: 10.4254/wjh.v9.i36.1346] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
107 Abdel-Wahab R, Shehata S, Hassan MM, Habra MA, Eskandari G, Tinkey PT, Mitchell J, Lee JS, Amin HM, Kaseb AO. Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. J Hepatocell Carcinoma 2015;2:131-42. [PMID: 27508202 DOI: 10.2147/JHC.S81309] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
108 Goh BK, Chow PK, Teo JY, Wong JS, Chan CY, Cheow PC, Chung AY, Ooi LL. Number of nodules, Child-Pugh status, margin positivity, and microvascular invasion, but not tumor size, are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma. J Gastrointest Surg. 2014;18:1477-1485. [PMID: 24855028 DOI: 10.1007/s11605-014-2542-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
109 Chu KKW, Cheung TT. Update in management of hepatocellular carcinoma in Eastern population. World J Hepatol 2015; 7(11): 1562-1571 [PMID: 26085915 DOI: 10.4254/wjh.v7.i11.1562] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
110 Sokolowski KM, Balamurugan M, Kunnimalaiyaan S, Wilson J, Gamblin TC, Kunnimalaiyaan M. Role of Akt inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy. Am J Surg 2016;211:755-60. [PMID: 26850133 DOI: 10.1016/j.amjsurg.2015.11.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
111 Berger NG, Tanious MN, Hammad AY, Miura JT, Mogal H, Clarke CN, Christians KK, Tsai S, Gamblin TC. External radiation or ablation for solitary hepatocellular carcinoma: A survival analysis of the SEER database. J Surg Oncol 2017;116:307-12. [PMID: 28464313 DOI: 10.1002/jso.24661] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
112 Aly A, Malangone-Monaco E, Noxon V, Henriques C, Benavente F, Kim A. Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma. Curr Med Res Opin 2020;36:1813-23. [PMID: 32969741 DOI: 10.1080/03007995.2020.1824899] [Reference Citation Analysis]
113 Sohn W, Paik Y, Kim JM, Kwon CH, Joh JW, Cho JY, Gwak G, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. HBV DNA and HBsAg Levels as Risk Predictors of Early and Late Recurrence after Curative Resection of HBV-related Hepatocellular Carcinoma. Ann Surg Oncol 2014;21:2429-35. [DOI: 10.1245/s10434-014-3621-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 6.3] [Reference Citation Analysis]
114 Qi W, Liang W, Jiang H, Miuyee Waye M. The function of miRNA in hepatic cancer stem cell. Biomed Res Int 2013;2013:358902. [PMID: 24383051 DOI: 10.1155/2013/358902] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
115 D'Alessandro LA, Meyer R, Klingmüller U. Hepatocellular carcinoma: a systems biology perspective. Front Physiol 2013;4:28. [PMID: 23444340 DOI: 10.3389/fphys.2013.00028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
116 Lashen SA, Elshafei MM, Hablass FH, Alsayed EA, Hassan AA. Liver stiffness as a predictor of hepatocellular carcinoma behavior in patients with hepatitis C related liver cirrhosis. Hepatobiliary Pancreat Dis Int 2020;19:22-8. [PMID: 31831335 DOI: 10.1016/j.hbpd.2019.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
117 Lai HC, Yeh CC, Jeng LB, Huang SF, Liao PY, Lei FJ, Cheng WC, Hsu CL, Cai X, Chang C, Ma WL. Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells. Oncotarget 2016;7:46448-65. [PMID: 27340775 DOI: 10.18632/oncotarget.10186] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
118 Krishnamurthy S, Gilot D, Ahn SB, Lam V, Shin JS, Guillemin GJ, Heng B. Involvement of Kynurenine Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5180. [PMID: 34680327 DOI: 10.3390/cancers13205180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr Oncol Rep. 2012;14:257-266. [PMID: 22434314 DOI: 10.1007/s11912-012-0233-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
120 Kim B, Suh K, Lee J, Woo SR, Park I, Park S, Han CJ, Kim S, Jeong S, Yeom YI, Yang S, Kim C, Cho SJ, Yoo YD, Cho M, Jang JJ, Choi DW, Lee K. Integrated Analysis of Prognostic Gene Expression Profiles from Hepatitis B Virus-Positive Hepatocellular Carcinoma and Adjacent Liver Tissue. Ann Surg Oncol 2012;19:328-38. [DOI: 10.1245/s10434-011-1709-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
121 Chang KH, Hwang ZA, Chang PY, Lin HH, Shih YL, Chang WC, Huang GS, Hsu HH. Predictive imaging for tumor response to drug-eluting microsphere transarterial chemoembolization in patients with BCLC-C advanced hepatocellular carcinoma. Sci Rep 2019;9:20032. [PMID: 31882969 DOI: 10.1038/s41598-019-56545-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 Hoffmann R, Rempp H, Syha R, Ketelsen D, Pereira PL, Claussen CD, Clasen S. Transarterial chemoembolization using drug eluting beads and subsequent percutaneous MR-guided radiofrequency ablation in the therapy of intermediate sized hepatocellular carcinoma. Eur J Radiol. 2014;83:1793-1798. [PMID: 25052871 DOI: 10.1016/j.ejrad.2014.06.031] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
123 Huang PJ, Chiu CC, Hsiao MH, Yow JL, Tzang BS, Hsu TC. Potential of antiviral drug oseltamivir for the treatment of liver cancer. Int J Oncol 2021;59:109. [PMID: 34859259 DOI: 10.3892/ijo.2021.5289] [Reference Citation Analysis]
124 Eltawil KM, Berry R, Abdolell M, Molinari M. Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre. HPB (Oxford) 2012;14:162-70. [PMID: 22321034 DOI: 10.1111/j.1477-2574.2011.00420.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
125 Marrero JA, Kudo M, Bronowicki JP. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist. 2010;15 Suppl 4:23-33. [PMID: 21115578 DOI: 10.1634/theoncologist.2010-s4-23] [Cited by in Crossref: 79] [Cited by in F6Publishing: 47] [Article Influence: 7.2] [Reference Citation Analysis]
126 Baffy G. Decoding multifocal hepatocellular carcinoma: an opportune pursuit. Hepatobiliary Surg Nutr 2015;4:206-10. [PMID: 26151061 DOI: 10.3978/j.issn.2304-3881.2014.12.05] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
127 Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011;29:3892-9. [PMID: 21911725 DOI: 10.1200/JCO.2011.36.0636] [Cited by in Crossref: 83] [Cited by in F6Publishing: 54] [Article Influence: 7.5] [Reference Citation Analysis]
128 Luu HM, Klink C, Niessen W, Moelker A, Walsum Tv. Non-Rigid Registration of Liver CT Images for CT-Guided Ablation of Liver Tumors. PLoS One 2016;11:e0161600. [PMID: 27611780 DOI: 10.1371/journal.pone.0161600] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
129 Yoo JJ, Yu SJ, Lee B, Cho EJ, Lee JH, Kim SG, Kim YJ, Kim YS, Yoon JH. Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B. Gut Liver 2020;14:377-86. [PMID: 31533399 DOI: 10.5009/gnl19112] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
130 Tokumitsu Y, Shindo Y, Matsui H, Matsukuma S, Nakajima M, Suzuki N, Takeda S, Wada H, Kobayashi S, Eguchi H, Ueno T, Nagano H. Utility of scoring systems combining the product of tumor number and size with liver function for predicting the prognosis of patients with hepatocellular carcinoma after hepatectomy. Oncol Lett 2019;18:3903-13. [PMID: 31516601 DOI: 10.3892/ol.2019.10688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
131 Goh BKP, Teo J, Chan C, Lee S, Jeyaraj P, Cheow P, Chow PKH, Ooi LLPJ, Chung AYF. Importance of tumor size as a prognostic factor after partial liver resection for solitary hepatocellular carcinoma: Implications on the current AJCC staging system: Tumor Size as a Prognostic Factor of Solitary HCC. J Surg Oncol 2016;113:89-93. [DOI: 10.1002/jso.24099] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
132 Giakoustidis AE, Giakoustidis DE. Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. Immunotherapy 2017;9:197-206. [PMID: 28128716 DOI: 10.2217/imt-2016-0110] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
133 Hwang A, Shi C, Zhu E, Naaz F, Zhou P, Rasheed Z, Liu M, Jung LS, Duan B, Li J, Jiang K, Paka L, Gadhiya SV, Dana D, Ali Q, Yamin MA, Goldberg ID, Narayan P. Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH. PLoS One 2018;13:e0198937. [PMID: 29944670 DOI: 10.1371/journal.pone.0198937] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
134 Walling AM, Schreibeis-Baum H, Pimstone N, Asch SM, Robinson L, Korlekar S, Lorenz K, Nwajuaku T, Rosenfeld K. Proactive case finding to improve concurrently curative and palliative care in patients with end-stage liver disease. J Palliat Med 2015;18:378-81. [PMID: 25493552 DOI: 10.1089/jpm.2014.0265] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
135 Liu CY, Chen KF, Chen PJ. Treatment of Liver Cancer. Cold Spring Harb Perspect Med 2015;5:a021535. [PMID: 26187874 DOI: 10.1101/cshperspect.a021535] [Cited by in Crossref: 85] [Cited by in F6Publishing: 91] [Article Influence: 12.1] [Reference Citation Analysis]
136 Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: Present and future: Novel treatment for liver cancer. Journal of Gastroenterology and Hepatology 2012;27:862-72. [DOI: 10.1111/j.1440-1746.2012.07096.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
137 Bissoondial TL, Han Y, Mullan S, Pabla AK, Spahn K, Shi S, Zheng L, Zhou P, Jiang K, Prakash N, Bhutkar S, Ali Q, Li J, Hu Z, Pellicano AJ, Goldberg ID, Narayan P. Liver Biopsy Hydroxyproline Content Is a Diagnostic for Hepatocellular Carcinoma in Murine Models of Nonalcoholic Steatohepatitis. Diagnostics (Basel) 2020;10:E784. [PMID: 33020436 DOI: 10.3390/diagnostics10100784] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
138 Liu S, Yang TB, Nan YL, Li AH, Pan DX, Xu Y, Li S, Li T, Zeng XY, Qiu XQ. Genetic variants of cell cycle pathway genes predict disease-free survival of hepatocellular carcinoma. Cancer Med 2017;6:1512-22. [PMID: 28639733 DOI: 10.1002/cam4.1067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
139 Papatheofani V, Levidou G, Sarantis P, Koustas E, Karamouzis MV, Pergaris A, Kouraklis G, Theocharis S. HuR Protein in Hepatocellular Carcinoma: Implications in Development, Prognosis and Treatment. Biomedicines 2021;9:119. [PMID: 33513829 DOI: 10.3390/biomedicines9020119] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
140 Lange A, Muniraj T, Aslanian HR. Endoscopic Ultrasound for the Diagnosis and Staging of Liver Tumors. Gastrointest Endosc Clin N Am 2019;29:339-50. [PMID: 30846157 DOI: 10.1016/j.giec.2018.12.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
141 Mahassadi AK, Anzouan-Kacou Kissi H, Attia AK. The Prognostic Values of Neutrophil-to-lymphocyte Ratio and Platelet-to-Lymphocyte Ratio at Baseline in Predicting the In-hospital Mortality in Black African Patients with Advanced Hepatocellular Carcinoma in Palliative Treatment: A Comparative Cohort Study. Hepat Med 2021;13:123-34. [PMID: 34938131 DOI: 10.2147/HMER.S333980] [Reference Citation Analysis]
142 Seinstra BA, van Delden OM, van Erpecum KJ, van Hillegersberg R, Mali WP, van den Bosch MA. Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today? Insights Imaging. 2010;1:167-181. [PMID: 23100194 DOI: 10.1007/s13244-010-0027-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
143 Clark T, Maximin S, Meier J, Pokharel S, Bhargava P. Hepatocellular Carcinoma: Review of Epidemiology, Screening, Imaging Diagnosis, Response Assessment, and Treatment. Curr Probl Diagn Radiol. 2015;44:479-486. [PMID: 25979220 DOI: 10.1067/j.cpradiol.2015.04.004] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 11.4] [Reference Citation Analysis]
144 Peng G, Chai H, Ji W, Lu Y, Wu S, Zhao H, Li P, Hu Q. Correlating genomic copy number alterations with clinicopathologic findings in 75 cases of hepatocellular carcinoma. BMC Med Genomics 2021;14:150. [PMID: 34103027 DOI: 10.1186/s12920-021-00998-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Chan SL, Chan AT, Yeo W. Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both? Future Oncol. 2009;5:889-899. [PMID: 19663737 DOI: 10.2217/fon.09.64] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
146 Laskar DB, Ilyas G, Diaz D, Shao C. Shoulder Mass as the Initial Presentation of Metastatic Hepatocellular Carcinoma. ACG Case Rep J 2017;4:e72. [PMID: 28584845 DOI: 10.14309/crj.2017.72] [Reference Citation Analysis]
147 Tat Trung N, Duong DC, Tong HV, Hien TTT, Hoan PQ, Bang MH, Binh MT, Ky TD, Tung NL, Thinh NT, Sang VV, Thao LTP, Bock CT, Velavan TP, Meyer CG, Song LH, Toan NL. Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma. PLoS One 2018;13:e0196081. [PMID: 29672637 DOI: 10.1371/journal.pone.0196081] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
148 Walling AM, Schreibeis-Baum H, Pimstone N, Asch SM, Robinson L, Korlekar S, Lorenz K, Nwajuaku T, Rosenfeld K. Proactive case finding to improve concurrently curative and palliative care in patients with end-stage liver disease. J Palliat Med. 2015;18:378-381. [PMID: 25493552 DOI: 10.1089/jpm.2014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Choi DT, Kum HC, Park S, Ohsfeldt RL, Shen Y, Parikh ND, Singal AG. Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2019;17:976-987.e4. [PMID: 30616961 DOI: 10.1016/j.cgh.2018.10.031] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
150 Mukherjee TK, Malik P, Hoidal JR. The emerging role of estrogen related receptorα in complications of non-small cell lung cancers. Oncol Lett 2021;21:258. [PMID: 33664821 DOI: 10.3892/ol.2021.12519] [Reference Citation Analysis]
151 Carr BI, Bag HG, Ince V, Ogut Z, Tuncer A, Akbulut S, Ersan V, Usta S, Isik B, Yilmaz S. A simple 2-parameter blood test alert for the presence of small hepatocellular carcinomas. Clin Pract (Lond) 2021;18:1804-9. [PMID: 34966540] [Reference Citation Analysis]
152 Cai J, Tong Y, Huang L, Xia L, Guo H, Wu H, Kong X, Xia Q. Identification and validation of a potent multi-mRNA signature for the prediction of early relapse in hepatocellular carcinoma. Carcinogenesis 2019;40:840-52. [DOI: 10.1093/carcin/bgz018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
153 Kim KM, Sinn DH, Jung SH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients? Liver Int. 2016;36:1490-1497. [PMID: 26936471 DOI: 10.1111/liv.13107] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
154 Faria SC, Szklaruk J, Kaseb AO, Hassabo HM, Elsayes KM. TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications. Abdom Imaging. 2014;39:1070-1087. [PMID: 24695938 DOI: 10.1007/s00261-014-0130-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
155 Ke J, Liu F, Liu Y. Glissonean Pedicle Transection with Hepatic Vein Exclusion for Hepatocellular Carcinoma: A Comparative Study with the Pringle Maneuver. Journal of Laparoendoscopic & Advanced Surgical Techniques 2020;30:58-63. [DOI: 10.1089/lap.2019.0484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
156 Liu P, Tan XZ, Zhang T, Gu QB, Mao XH, Li YC, He YQ. Prediction of microvascular invasion in solitary hepatocellular carcinoma ≤ 5 cm based on computed tomography radiomics. World J Gastroenterol 2021; 27(17): 2015-2024 [PMID: 34007136 DOI: 10.3748/wjg.v27.i17.2015] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
157 Kapitanov T, Neumann UP, Schmeding M. Hepatocellular Carcinoma in Liver Cirrhosis: Surgical Resection versus Transarterial Chemoembolization-A Meta-Analysis. Gastroenterol Res Pract 2015;2015:696120. [PMID: 25642245 DOI: 10.1155/2015/696120] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
158 Kim PT, Jang JH, Atenafu EG, Fischer S, Greig PD, McGilvray ID, Wei AC, Gallinger S, Cleary SP. Outcomes after hepatic resection and subsequent multimodal treatment of recurrence for multifocal hepatocellular carcinoma. Br J Surg. 2013;100:1516-1522. [PMID: 24037575 DOI: 10.1002/bjs.9263] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
159 Abraham JA, Golubnitschaja O. Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon? Per Med 2016;13:455-67. [PMID: 29767598 DOI: 10.2217/pme-2016-0013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
160 Fernández-Ruiz M, Guerra-Vales JM, Vila-Santos J, Colina-Ruizdelgado F. [Prognostic prediction in patients with hepatocellular carcinoma not amenable to locoregional treatment]. Med Clin (Barc) 2009;133:581-5. [PMID: 19748634 DOI: 10.1016/j.medcli.2009.06.053] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
161 Zhang W, Hu B, Han J, Wang Z, Ma G, Ye H, Yuan J, Cao J, Zhang Z, Shi J, Chen M, Wang X, Xu Y, Cheng Y, Tian L, Wang H, Lu S. Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients. Front Oncol 2021;11:747950. [PMID: 34737958 DOI: 10.3389/fonc.2021.747950] [Reference Citation Analysis]
162 Penzkofer L, Huber T, Mittler J, Lang H, Heinrich S. [Liver Resections Can Be Safely Performed in Cirrhotic Patients after Careful Patient Selection]. Zentralbl Chir 2021. [PMID: 33663000 DOI: 10.1055/a-1373-6218] [Reference Citation Analysis]
163 Radjenović B, Sabo M, Šoltes L, Prnova M, Čičak P, Radmilović-Radjenović M. On Efficacy of Microwave Ablation in the Thermal Treatment of an Early-Stage Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5784. [PMID: 34830937 DOI: 10.3390/cancers13225784] [Reference Citation Analysis]